To conclude, our findings highlight Ctr1 as a potential molecular target to intervene Cu-mediated α-syn aggregation and pathology and extend a broader view for therapy of Cu dysmetabolism-related neurodegenerative diseases, such as AD, ALS, PD, and other synucleinopathies. Here, SLC31A1 is linked to neurodegenerative disease.